This could result in future studies designed to confirm the role of SP in the pathogenesis of pruritus in ICP patients and to assess the efficacy of topical or systemic NK1R antagonists, such as aprepitant and serlopitant, in providing relief from pruritus. The gene discussed is TFF2; the disease is Pruritus.